FIELD: biotechnology.
SUBSTANCE: group of inventions is described, comprising an antibody to CTLA4 (variants) and a multispecific antibody (variants) that are characterized by inhibiting the binding of CTLA4 to human B7, polynucleotides encoding the above antibodies or multispecific antibodies, an antibody expression vector to CTLA4, a host cell for expression of an antibody to CTLA4, a composition for the treatment of diseases associated with CTLA4, a composition for the diagnosis of diseases associated with CTLA4, a method for the treatment diseases associated with human CTLA4, a method of treating cancer, development of the above antibodies or multispecific antibodies for the detection of in vitro or in vivo presence of the human CTLA4 antigen to diagnose diseases associated with human CTLA4, the use of the above antibodies or multispecific antibodies for the treatment of diseases associated with human CTLA4.
EFFECT: invention extends the arsenal of antibodies to CTLA4.
31 cl, 18 dwg, 2 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANIZED ANTIBODY TO CD52 | 2012 |
|
RU2605307C2 |
| HUMANIZED MONOCLONAL ANTIBODY RAISED AGAINST AILIM, CO-STIMULATING MOLECULE FOR SIGNAL TRANSFER AND ITS PHARMACEUTICAL APPLYING | 2001 |
|
RU2262511C2 |
| ANTISUBSTANCES AGAINST GLOBULOMER Aβ, THEIR ANTIGEN-BINDING PARTS, CORRESPONDING HYBRIDOMAS, NUCLEIC ACIDS, VECTORS, HOST CELLS, WAYS OF PRODUCTION OF MENTIONED ANTISUBSTANCES, COMPOSITIONS CONTAINING MENTIONED ANTISUBSTANCES, APPLICATION OF MENTIONED ANTISUBSTANCES AND WAYS OF APPLICATION OF MENTIONED ANTISUBSTANCES | 2006 |
|
RU2442793C2 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
| MONOVALENT CARRIER MODULES ACROSS BLOOD-BRAIN BARRIER | 2014 |
|
RU2694659C2 |
| UNIVERSAL TRANSMITTER MODULES THROUGH THE HEMATOENCEPHALITIC BARRIER | 2014 |
|
RU2799436C1 |
| IL2 ANTIBODIES | 2006 |
|
RU2425054C2 |
| THERAPEUTIC BINDING MOLECULES | 2002 |
|
RU2328506C2 |
| ANTIBODY FOR BLyS | 2013 |
|
RU2613422C2 |
| ANTIBODY AGAINST LAG-3, ITS ANTIGEN-BINDING FRAGMENT AND THEIR PHARMACEUTICAL APPLICATION | 2017 |
|
RU2757813C2 |
